Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Indaptus Therapeutics Inc

INDP ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: N/A

Last Close

$3.16

▲ +6.76%

Market Cap $485.32M · Vol 70.76K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$485.32M

Small Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

68.98

Momentum

Beta

1.01

vs Market

52W High

$5.95

50.25% below

52W Low

$0.93

220.00% above

Volume

70.76K

Avg 151.65K

P/B

2.01

Price-to-book

ROE

N/A

Return on equity

Free Float

28.48%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Indaptus Therapeutics Inc (INDP) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INDP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+42.99%

+2.27%

+25.40%

-10.73%

YTD

+8.59%

-11.98%

-95.49%

-98.54%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-20,848,920.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-250.45% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.01
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	153.58M

Technical Indicators

50-Day SMA	$2.24
200-Day SMA	$2.28
RSI (14)	68.98
Beta	1.01
52-Week High	$5.95
52-Week Low	$0.93

Volume Today	70.76K
Avg Daily Volume (30D)	151.65K
Relative Volume	0.47x
Volatility (10D)	145.79
Volatility (30D)	198.09
Free Float	28.48%

Analyst Consensus

N/A

Current Price $3.16

Mean Target N/A

52W Low$0.93 52W High$5.95

Current

Target

$0.93 $5.95

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00ZNLVBD7

ISINUS45339J2042

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.22% ONC BeOne Medicines AG +0.51% 068270.KS Celltrion, Inc. +0.10% MEDP Medpace Holdings, Inc. +6.43% CRL Charles River Laboratories International, Inc. +9.33%

Company Profile

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.